Amaral Ana Luisa, Lwaleed Bashir Abdulgader, Bouquot Jerry Elmer, Andrade Sérgio Araújo
Faculty of Dentistry, University of Itaúna (UIT), Itaúna, MG, Brazil.
Research Center on Biological Chemistry (NQBio), Federal University of São João del-Rei (UFSJ), Divinópolis, MG, Brazil.
Evid Based Dent. 2024 Dec;25(4):176-177. doi: 10.1038/s41432-024-01026-2. Epub 2024 Jun 12.
A comprehensive search was conducted on PubMed and Embase, adhering to the principles outlined in the PRISMA Extension for Scoping Reviews (PRISMA-ScR). The search strategy was subsequently registered on PROSPERO.
Articles were chosen based on an analysis of titles and abstracts, with no restrictions on publication date, language, or participant age. In vitro studies, animal studies, and literature reviews were excluded from consideration.
Clinical trials in humans, case reports, or case series that reported the use of imiquimod for treating conditions in the oral or labial mucosa were included in this study. Results from duplicate articles were excluded from the analysis.
Out of a total of 601 references initially identified, only 28 studies were included in the review. These studies were classified based on the use of imiquimod into three groups: potentially malignant disorders and oral cancer, lesions related to HPV, and autoimmune conditions. In all cases presented in the article, there is an occurrence of both local and systemic side effects.
The study elucidated the off-label use of imiquimod in oral pathologies, whether potentially malignant, cancerous, autoimmune, or associated with HPV infection. However, it was observed that further research is warranted for the development of a specific formulation for the oral mucosa, ensuring the drug's sustained presence at its active site of action without interference from saliva and minimizing potential side effects.
按照《系统综述扩展版的首选报告项目：范围综述》（PRISMA-ScR）中概述的原则，对PubMed和Embase进行了全面检索。检索策略随后在PROSPERO上进行了注册。
根据标题和摘要分析来选择文章，对发表日期、语言或参与者年龄没有限制。体外研究、动物研究和文献综述不纳入考虑范围。
本研究纳入了关于使用咪喹莫特治疗口腔或唇黏膜疾病的人体临床试验、病例报告或病例系列。重复文章的结果被排除在分析之外。
在最初确定的总共601篇参考文献中，该综述仅纳入了28项研究。这些研究根据咪喹莫特的用途分为三组：潜在恶性疾病和口腔癌、与HPV相关的病变以及自身免疫性疾病。文章中呈现的所有病例均出现了局部和全身副作用。
该研究阐明了咪喹莫特在口腔病理学中的超说明书使用情况，无论是潜在恶性、癌变、自身免疫性还是与HPV感染相关的情况。然而，观察到有必要进一步开展研究，以开发一种针对口腔黏膜的特定制剂，确保药物在其活性作用部位持续存在，不受唾液干扰，并将潜在副作用降至最低。
